Journal of Gastrointestinal Infections

Register      Login

VOLUME 2 , ISSUE 1 ( 2012 ) > List of Articles

ORIGINAL ARTICLE

Clinical Profile of Hepatorenal Syndrome: A Prospective Study

Sandeep Puri, Praveen Rishi, Rajoo Singh Chhina, Rajdeep Singh Chhina, Amit Bery, Jaswinder Singh Sandhu

Keywords : Hepatorenal syndrome, outcome, survival

Citation Information : Puri S, Rishi P, Chhina RS, Chhina RS, Bery A, Sandhu JS. Clinical Profile of Hepatorenal Syndrome: A Prospective Study. J Gastrointest Infect 2012; 2 (1):38-42.

DOI: 10.5005/jogi-2-1-38

License: CC BY-SA 4.0

Published Online: 01-06-2012

Copyright Statement:  Copyright © 2012; Jaypee Brothers Medical Publishers (P) Ltd.


Abstract

Background and Objectives: The clinical profile of hepatorenal syndrome (HRS) patients admitted in a tertiary care hospital of Punjab was studied. Methods: In this prospective study all the patients of chronic liver disease with renal involvement fulfilling the International Ascites Club criteria of HRS were evaluated over a period of one and a half year. Result: Forty-two patients were diagnosed to have HRS and were included in the study. The incidence of HRS was 0.275%of hospitalmedical admissions. Alcoholic cirrhosis was the etiology in 71.5%of patients. Most of the patients of HRS received a combination of dopamine, albumin and terlipressin. Themortality ratewas found to be approximately 60%. Variables amongst survival versus non-survival groups were analyzed. Oliguria and hepatic encephalopathy weremore predominant in non-survival group. Serumbilirubin, hypoalbuminemia, hyponatremia, coagulopathy and urine osmolalitywas higher in non-survival group. Patients with Child-Pugh Score less than 10 had a better survival. Conclusion: The poor prognostic factors in non-survival group were presence of ascites, severe jaundice, hepatic encephalopathy, alcohol abuse, hypoalbuminemia, progressive renal failure and a Child-Pugh Score > 10. Thus, HRS is not uncommon and needs proper diagnosis and prompt treatment to ensure better outcome.


PDF Share
  1. Turban S, Thuluvath PJ, Atta MG. Hepatorenal syndrome. World J Gastroenterol 2007;13(30):4046-55.
  2. Wilkinson SP, Blendis LM, Williams R. Frequency and type of renal and electrolyte disorders in fulminant hepatic failure. Br Med J1974;1:186-9.
  3. Santiago JM. The hepatorenal syndrome. Med Clin North Am 2008;92(4):813-37.
  4. Arroyo V, Fernandez J, Gines P. Pathogenesis and treatment of hepatorenal syndrome. Semin liver dis 2008;28(1):81-95.
  5. Watt K, Uhanova J, Minuk GY. Hepatorenal syndrome: diagnostic accuracy, clinical features, and outcome in a tertiary care centre. Am J Gastroenterol 2002;97(8):2046-50.
  6. Moreau R, Durand F, Poynard T, Duhamel C, Cervoni JP, Ichaï P, et al. Terlipressin in patients with cirrhosis and type 1 HRS: A retrospective multicenter study. Gastroenterol 2002;122(4):923-30.
  7. Butt AK, Khan AA, Alam A, Shah SW, Shafqat F, Naqvi AB. Predicting hospital mortality in cirrhotic patients: comparison of Child-Pugh and Acute Physiology, Age and Chronic Health Evaluation (APACHE III). Am J Gastroenterol 1998;93(12):2469-75.
  8. Solerno F, Barroni G, Moser P, Badalamenti S, Cassarà L, Maggi A, et al. Survival and prognostic factors of cirrhotic patients with ascites; a study of 134 patients. Am J Gastroenterol 1993;88(4):514-9.
  9. Epstein M, Berk DP, Hallenberg NK, Adams DF, Chalmers TC, Abrams HL, et al. Renal failure in the patients with cirrhosis; the role of active vasoconstriction. Am J Med 1970;49(2):175-85.
  10. Porcel A, Diaz F, Rendon P, Macias M, Martin-Herrera L, Giron- Gonzalez JA. Dilutional hyponatremia in patients with cirrhosis and ascites. Arch Intern Med 2002;162(3):323-8.
  11. Uriz J, Gines P, Cardenas A, Sort P, Jimenez W, Salmeron JM, et al. Terlipressin plus albumin infusion: an effective and safe therapy of hepatorenal syndrome. J Hepatol 2000;33(1):43-8.
  12. Hadengue A, Gadano A, Moreau R, Giostra E, Durand F, Valla D, et al. Beneficial effects of the 2-day administration of terlipressin in patientswith cirrhosis and hepatorenal syndrome. J Hepatol 1998;29(4):565-70.
  13. Colle I, Durand F, Pessione F, Rassiat E, Bernuau J, Barriere E, et al. Clinical course, predictive factors and prognosis in patients with cirrhosis and type 1 hepatorenal syndrome treated with terlipressin: a retrospective analysis. J Gastroenterol Hepatol 2002;17(8):882-8. PDF created
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.